Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2025 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025

VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering,...
January 13, 2025 08:30 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Outlines Key Corporate Milestone Opportunities for 2025

– Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch of azetukalner – First of three planned Phase 3 MDD...
January 07, 2025 08:30 ET | Source: Xenon Pharmaceuticals Inc.

Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference

VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering,...
December 06, 2024 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

– OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner –...
November 25, 2024 08:30 ET | Source: Xenon Pharmaceuticals Inc.

Xenon to Showcase New Long-Term Azetukalner Data at AES 2024

Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS and findings around mental health and comorbidity burdens of FOSNew...
November 13, 2024 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia and BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering,...
November 12, 2024 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Reports Q3 2024 Financial Results and Business Update

– Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES – Phase...
November 05, 2024 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon to Report Q3 2024 Financial Results on November 12, 2024

VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering,...
October 02, 2024 16:28 ET | Source: Xenon Pharmaceuticals Inc.

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference

VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering,...
September 09, 2024 08:30 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress

Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal onset seizures VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) --...